Microalgae products hold promising potentials to combat the morbidity and mortality associated with the novel coronavirus. Antiviral compounds in cyanobacterial lectins, including agglutinin OAA and cyanovirin-N (CV-N) are bring publicized for inhibiting a range of viruses. Such findings have brought companies in the Europe microalgae products market under great scrutiny. Stakeholders are increasing their R&D capabilities in pharmaceutical products that help increase immunity levels of individuals.